Longeveron LGVN 深 沪
等待开盘 08-10 09:30:00 美东时间
0.766
-0.007
-0.97%
华盛通- 最 高0.80
- 今 开0.777
- 成交量 38.86万股
- 最 低 0.72
- 昨 收 0.7735
- 总市值 1.60万
- 52周最高 1.23
- 市盈率 静 --
- 换手率 1855.99%
- 52周最低 0.475
- 委 比 -17.16%
- 总股本 2.09万
- 历史最高 45.00
- 量 比 0.87
- 振 幅 10.34%
- 历史最低 0.3313
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron Alzheimer’s Therapy Shows Brain Inflammation Benefits, Presents New Alzheimer’s Stem Cell Therapy Data
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of
07-13 19:17
Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines Agency
According to the EMA, SME Designation has allowed for improved success rate for organizations seeking regulatory approvals:the success rate for SME marketing authorization applications for human medicines more than
06-09 21:21
Maxim Group Downgrades Longeveron to Hold
Maxim Group analyst Michael Okunewitch downgrades Longeveron (NASDAQ:LGVN) from Buy to Hold.
05-12 03:42
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal
Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.
03-11 03:58
Longeveron Commences $30M Private Placement
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it has entered into a
03-10 21:05
Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_02262026_LGVN_Sorensen.pdf
02-27 00:05
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Longeveron Inc.'s CEO, Wa’el Hashad, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 16-17, 2025. A pre-recorded presentation will be available on June 16 at 7:00 a.m. ET via the provided link. Longeveron is developing cellular therapies for aging-related conditions, with its lead product, laromestrocel, targeting hypoplastic left heart syndrome, Alzheimer’s disease, and aging-related frailty.
2025-06-09 13:15
Longeveron Publishes Results Of Phase 2a Clinical Trial Evaluating Laromestrocel In Alzheimer's Disease In Nature Medicine
Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data adds to the
2025-03-11 20:31
Longeveron Announces Type C Meeting With U.S. FDA Regarding Pathway to BLA for Lomecel-B In Hypoplastic Left Heart Syndrome
On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for potential full traditional approval Alignment with FDA on ELPIS II primary and secondary endpoints Alignment with FDA on CMC and Potency Assay plan and requ...
2024-09-03 21:03
Beyond The Numbers: 4 Analysts Discuss Longeveron Stock
In the preceding three months, 4 analysts have released ratings for Longeveron (NASDAQ:LGVN), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to ...
2024-08-27 23:00
